Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 13/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 13/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1547311 | 0.95 | KMT2A (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1546722 | 0.93 | KMT2A (0.57) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL31543865 | 0.90 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1547374 | 0.90 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3490895 | 0.89 | KMT2A (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL308621 | 0.89 | KMT2A (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10258244 | 0.86 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12262202 | 0.86 | KMT2A (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL12262177 | 0.84 | KMT2A (0.69) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1546859 | 0.83 | HDAC3 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980877-B2 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.R.L. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2488529-B1 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC SRL (IT) | 2014-08-20 | — | — | EP | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120258949-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | DAC S.r.I. (IT) | 2012-10-11 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2311840-A1 | Spirocyclic derivatives as histone deacetylase inhibitors | DAC S.r.l. (IT) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | HDAC3 1520/4885HDAC4 1303/4885HDAC1 366/4885 |
| US-20120258949-A1 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC4, HDAC1 | HDAC3 1/4885HDAC4 2/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.